Dysmenorrhea

IGC Reports Financial Results for Second Fiscal Quarter Ended Sept. 30, 2022

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, THC, IGC, Marketing, Failure, Annual report, Risk, CEO, USF, CBD, SEC, Capsule, Research, PMS, Dysmenorrhea, In Defense of Global Capitalism, NYSE, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research and development, Safety, Patent, Dementia, University, Neurotoxicity, Health Canada, Company, Phase II, Woman, FDA, Patient, Food, Agitation, Premenstrual syndrome, Depreciation, Chronic pain, Pharmaceutical industry, Fine chemical

India Globalization Capital, Inc. (NYSE American: IGC) (IGC or the Company) today reported its second fiscal quarter 2023 financial results.

Key Points: 
  • India Globalization Capital, Inc. (NYSE American: IGC) (IGC or the Company) today reported its second fiscal quarter 2023 financial results.
  • Sales of the Companys CBD-infused products and services increased about 345% for the six-months ended September 30, 2022 compared to the six-months ended September 30, 2021.
  • Revenue was approximately $202,000 for the three months ended Sept. 30, 2022, compared to $56,000 for the three months ended Sept. 30, 2021.
  • Research and Development (R&D) expenses were $768,000 for the three months ended Sept. 30, 2022, compared to approximately $276,000 for the three months ended Sept. 30, 2021.

Channel Medsystems Announces First Endometrial Ablation Procedures in Europe with the Cerene® Cryotherapy Device

Retrieved on: 
Monday, October 3, 2022
General Health, Health, Medical Devices, Bleeding, Uterus, Physician, Light, Anesthesia, Dysmenorrhea, Pain, Channel, CA, Gynaecology, Harwell Science and Innovation Campus, Journal, Cryotherapy, HMB, Ceren, Patient, Innovation, Woman, Endometrium, Birth control, Science

Channel Medsystems, Inc. , a medical device company whose mission is to empower every woman to take control of her health journey, today announced that the first procedures in Europe were performed with the Cerene Cryotherapy Device for the treatment of heavy menstrual bleeding (HMB).

Key Points: 
  • Channel Medsystems, Inc. , a medical device company whose mission is to empower every woman to take control of her health journey, today announced that the first procedures in Europe were performed with the Cerene Cryotherapy Device for the treatment of heavy menstrual bleeding (HMB).
  • Cerene Cryotherapy provides an endometrial ablation treatment using cooling technology (cryoablation) that can significantly reduce menstrual bleeding and dysmenorrhea.
  • The Cerene Cryotherapy Device received a CE Mark for endometrial ablations in premenopausal women with heavy menstrual bleeding due to benign causes for whom childbearing is complete.
  • We are pleased that our first procedures demonstrated the potential of the Cerene Cryotherapy Device to safely treat patients with heavy menstrual bleeding in an office environment with minimal anesthesia.

XpresSpa Group Expands Retail Products for Women, Underscoring Company’s Commitment to Support Women’s Health and Wellness

Retrieved on: 
Wednesday, September 21, 2022
Well, Pure, Health, Time-invariant system, Cramp, Temperature, Sex, Woman, COVID-19, Social responsibility, Severe acute respiratory syndrome coronavirus 2, Concentric objects, Breast cancer, UTI, Company, Ovulation, Herbal, Dysmenorrhea, Pregnancy, Travel, Reproductive health, Technology, Global health, Heat, CDC, Solution, Nasdaq, Breast Cancer Awareness Month, STD, Sleep, Bloating, Committee, Research, Digital, GLOBE, Airport, Education, Color, Ginkgo, Birth control, Cosmetics, Pharmaceutical industry

As part of this launch, the Company rolled out an expanded line of retail products dedicated to womens health including products in the personal hygiene, pregnancy prevention, reproductive health, first aid and wellness categories.

Key Points: 
  • As part of this launch, the Company rolled out an expanded line of retail products dedicated to womens health including products in the personal hygiene, pregnancy prevention, reproductive health, first aid and wellness categories.
  • We want to deliver solutions that inform and serve their evolving lifestyles and meet their specific health and wellness needs, said XpresSpa Group CEO Scott Milford.
  • We created the Womens Health Initiative to increase the Companys support for women and to provide enhanced education and access to health and wellness solutions for women on the go.
  • XpresSpa Group, Inc.(Nasdaq: XSPA) is a leading global health and wellness holding company operating four brands: XpresCheck,XpresSpa, Treat and HyperPointe.

Therabody Solidifies Category Leadership with $165 Million Growth Equity Round and Launch of Eight New Innovative Products

Retrieved on: 
Tuesday, September 20, 2022
Minter, Avalon, Central nervous system, IOS, Pains, Face, MSRP, Social media, Environment, Investment, Injury, Anxiety, Ecosystem, Android, Sleep, Massage, Rehabilitation, PRO, NPD, ACHES, NEW, Juice, Relaxation, Octane Fitness, LLC v. ICON Health & Fitness, Inc., Pain, Heat, Science, DNA, Color, Software, Hydro massage, News, Full Swing, The NPD Group, Facial muscles, Heart rate, Sport, Plastic, Motion, Echelon, Dysmenorrhea, Reset, Athlete, Equinox Group, LLC, Headache, EAS, OLED, Cascade, Vitamin, Vibration, Pharmaceutical industry, Medical imaging, Mobile phone, Video game console, Boot camp

LOS ANGELES, Sept. 20, 2022 /PRNewswire/ -- TherabodyⓇ, the global pioneer in wellness technology, announced today the close of its growth equity round with a total financial backing of $165 million, alongside the launch of eight new products that expand the brand to whole-body wellness with proven benefits across performance, pain, stress, and sleep.

Key Points: 
  • With this unique combination of offerings, Therabody aims to inspire and enable consumers to keep their minds and bodies in motion.
  • In February 2021, Therabody completed its first capital raise , filling its prominent roster of investors with athletes, financial sponsors, cultural influencers, and other celebrities.
  • To learn more about Therabody and its upcoming news, please visit therabody.com and follow @therabody on social media.
  • For more information, please download the Therabody App for iOS or Android , visit www.therabody.com , or follow @therabody on social media.

Therabody Solidifies Category Leadership with $165 Million Growth Equity Round and Launch of Eight New Innovative Products

Retrieved on: 
Tuesday, September 20, 2022
Minter, Avalon, Central nervous system, IOS, Pains, Face, MSRP, Social media, Environment, Investment, Injury, Anxiety, Ecosystem, Android, Sleep, Massage, Rehabilitation, PRO, NPD, ACHES, NEW, Juice, Relaxation, Octane Fitness, LLC v. ICON Health & Fitness, Inc., Pain, Heat, Science, DNA, Color, Software, Hydro massage, News, Full Swing, The NPD Group, Facial muscles, Heart rate, Sport, Plastic, Motion, Echelon, Dysmenorrhea, Reset, Athlete, Equinox Group, LLC, Headache, EAS, OLED, Cascade, Multimedia, Vitamin, Vibration, Pharmaceutical industry, Medical imaging, Mobile phone, Video game console, Boot camp

LOS ANGELES, Sept. 20, 2022 /PRNewswire/ -- TherabodyⓇ, the global pioneer in wellness technology, announced today the close of its growth equity round with a total financial backing of $165 million, alongside the launch of eight new products that expand the brand to whole-body wellness with proven benefits across performance, pain, stress, and sleep.

Key Points: 
  • Therabody announced today the close of its growth equity round of $165M, alongside the launch of eight new products.
  • With this unique combination of offerings, Therabody aims to inspire and enable consumers to keep their minds and bodies in motion.
  • In February 2021, Therabody completed its first capital raise , filling its prominent roster of investors with athletes, financial sponsors, cultural influencers, and other celebrities.
  • For more information, please download the Therabody App for iOS or Android , visit www.therabody.com , or follow @therabody on social media.

The Worldwide Non-steroidal Anti-inflammatory Drugs Industry is Expected to Reach $25.5 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 19, 2022
Health, Other Health, Headache, Dizziness, Enzyme, Inflammation, Allergy, Civilization, Incidence, Prevalence, Nonsteroidal anti-inflammatory drug, Ulcerative colitis, Population, Time-invariant system, Growth, NSAID, Drug tolerance, Analgesic, Person, Aspirin, Naproxen, Ibuprofen, COX-1, History, OTC, Pain, Migraine, Injury, Disorder, CDC, Toothache, Dysmenorrhea, Abdominal pain, Pain scale, Chronic pain, Birth control, Poultry

Inflammation is caused by the COX-1 and COX-2 enzymes that are inhibited by non-steroidal anti-inflammatory medications (NSAIDs).

Key Points: 
  • Inflammation is caused by the COX-1 and COX-2 enzymes that are inhibited by non-steroidal anti-inflammatory medications (NSAIDs).
  • The market for non-steroidal anti-inflammatory medications (NSAIDs) is expanding as a result of a number of causes, including the growing incidence of chronic pain worldwide and an ageing population.
  • For instance, the CDC estimates that in the United States, about 20,4% of adults experienced chronic pain in 2019.
  • Compared to Hispanic, non-Hispanic Asian, and non-Hispanic black individuals, non-Hispanic whites had the highest prevalence of chronic pain.

Global Non-steroidal Anti-inflammatory Drugs Market Report 2022: Rising Prevalence of Targeted Diseases and Chronic Pain Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 15, 2022
Retail, Health, Consumer, Convenience Store, Seniors, Supermarket, Pharmaceutical, National, Adoption, Inflammation, HEAL, Arthritis, Prevalence, Nonsteroidal anti-inflammatory drug, Nasal administration, Headache, Growth, Thermoregulation, Market share, Migraine, Osteoarthritis, USD, OTC, Laboratory, Pain, Route of administration, Patient-Centered Outcomes Research Institute, Dysmenorrhea, Sprain, Pain management, Wickham Laboratories Ltd, Fever, Chronic pain, CAGR, Pharmaceutical industry, Fine chemical

The global non-steroidal anti-inflammatory drugs market is expected to reach USD 31.29 billion by 2030, expanding at a CAGR of 5.36% during the forecast period.

Key Points: 
  • The global non-steroidal anti-inflammatory drugs market is expected to reach USD 31.29 billion by 2030, expanding at a CAGR of 5.36% during the forecast period.
  • Nonsteroidal anti-inflammatory drugs are drugs that are primarily used to relieve inflammation and pain, as well as to lower elevated body temperature.
  • The non-steroidal anti-inflammatory drugs market is expected to witness growth opportunities owing to factors such as the rising prevalence of targeted diseases and chronic pain across the globe, coupled with the high prevalence of these diseases in the geriatric population.
  • Moreover, increasing approval of OTC drugs for pain management and other inflammatory diseases is expected to drive growth during the forecast period.

Dysmenorrhea Drug Pipeline Market Report 2022: Assessment by Product Type, Stage, Route of Administration, and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Monday, September 12, 2022
Health, Pharmaceutical, Therapy, II, Glutamate synthase (NADPH), Route of administration, 001, Administration, Back pain, PNB, News, Osteoarthritis, Route, Clinical trial, III, Discovery, Medical device, Pharmaceutical industry, Dysmenorrhea, Dysmenorrhea

This "Dysmenorrhea - Pipeline Insight, 2022" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Dysmenorrhea pipeline landscape.

Key Points: 
  • This "Dysmenorrhea - Pipeline Insight, 2022" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Dysmenorrhea pipeline landscape.
  • It covers the pipeline drug profiles, including clinical and nonclinical stage products.
  • It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
  • phase III include Daewon Pharmaceutical and others
    Dysmenorrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global Gynecology Partnering Deal Trends, Players and Financials Report/Directory 2010-2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
General Health, Other Professional Services, Professional Services, Health, Pelvic inflammatory disease, Chapter Six, Menopause, Technology, Research, HPV, Premenstrual syndrome, Finance, Players, Vaginitis, Chapter One, SEC, Orientation, CIN, Chapter Two, Chapter Three, Chapter Five, Directory, Cervical intraepithelial neoplasia, Hyperlink, Chapter Four, Adenomyosis, Primary ovarian insufficiency, Polycystic ovary syndrome, Polycystic disease, Review, Contract, Video game, Birth control, Risk management, Sales, Endometriosis, Prolapse, Infertility, Dysmenorrhea, Amenorrhea, Gynaecology

The "Global Gynecology Partnering 2010-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gynecology Partnering 2010-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Gynecology Partnering 2010-2022 report provides comprehensive access to available deals and contract documents for over 490 gynecology deals.
  • The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals.
  • Global Gynecology Partnering 2010 to 2022 includes:
    In Global Gynecology Partnering 2010 to 2022, available deals and contracts are listed by:

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Retrieved on: 
Saturday, August 6, 2022
Linda, FDA, Woman, Hospital, Dysmenorrhea, UCSF, Endometriosis, NYSE, Internal medicine, GLOBE, University of California, San Francisco, NEW, Senior, Norethisterone, Roivant Sciences, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pfizer, PFE, Pain, Patient, SPIRIT, Uterine fibroid, Safety, Rusyns, Webcast, Physician, University, Conditional sentence, Chair, Food, Health, Disease, Pharmaceutical industry, Dentistry, Lancet

MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Key Points: 
  • MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.
  • MYFEMBREE is available immediately to patients with moderate to severe pain associated with endometriosis with a prescription from their healthcare provider.
  • Myovant and Pfizer also are committed to supporting women in the U.S. who are prescribed MYFEMBREE throughout their treatment journeys.
  • Food and Drug Administration for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.